miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation.

MicroRNAs (miRNA) have been globally profiled in cancers but there tends to be poor agreement between studies including in the same cancers. In addition, few putative miRNA targets have been validated. To overcome the lack of reproducibility, we profiled miRNAs by next generation sequencing and locked nucleic acid miRNA microarrays and verified concordant changes by quantitative RT-PCR. Notably, miR-125b and the miR-99 family members miR-99a, -99b, and -100 were downregulated in all assays in advanced prostate cancer cell lines relative to the parental cell lines from which they were derived. All four miRNAs were also downregulated in human prostate tumor tissue compared with normal prostate. Transfection of miR-99a, -99b, or -100 inhibited the growth of prostate cancer cells and decreased the expression of prostate-specific antigen (PSA), suggesting potential roles as tumor suppressors in this setting. To identify targets of these miRNAs, we combined computational prediction of potential targets with experimental validation by microarray and polyribosomal loading analysis. Three direct targets of the miR-99 family that were validated in this manner were the chromatin-remodeling factors SMARCA5 and SMARCD1 and the growth regulatory kinase mTOR. We determined that PSA is posttranscriptionally regulated by the miR-99 family members, at least partially, by repression of SMARCA5. Together, our findings suggest key functions and targets of miR-99 family members in prostate cancer suppression and prognosis.

[1]  C. Creighton,et al.  Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.

[2]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[3]  Yi Wen Kong,et al.  How do microRNAs regulate gene expression? , 2008, Biochemical Society transactions.

[4]  P. Majumder,et al.  Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. , 2009, Cancer research.

[5]  William Ignace Wei,et al.  Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue , 2008, Clinical Cancer Research.

[6]  George A Calin,et al.  MicroRNAs and cancer: Profile, profile, profile , 2007, International journal of cancer.

[7]  L. Lim,et al.  An Abundant Class of Tiny RNAs with Probable Regulatory Roles in Caenorhabditis elegans , 2001, Science.

[8]  Jerry Pelletier,et al.  Short RNAs repress translation after initiation in mammalian cells. , 2006, Molecular cell.

[9]  N. Weigel,et al.  Androgen receptor action in hormone‐dependent and recurrent prostate cancer , 2006, Journal of cellular biochemistry.

[10]  T. Miyamoto,et al.  Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. , 1998, The Journal of urology.

[11]  G. Jenster,et al.  Functional screening of FxxLF-like peptide motifs identifies SMARCD1/BAF60a as an androgen receptor cofactor that modulates TMPRSS2 expression. , 2009, Molecular endocrinology.

[12]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[13]  M. Webber,et al.  Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  D. Reinberg,et al.  Purification and Characterization of a Human Factor That Assembles and Remodels Chromatin* , 2000, The Journal of Biological Chemistry.

[15]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[16]  A. Malhotra,et al.  Muscle-specific microRNA miR-206 promotes muscle differentiation , 2006, The Journal of cell biology.

[17]  Yi Wen Kong,et al.  The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene , 2008, Proceedings of the National Academy of Sciences.

[18]  Simon A. Williams,et al.  Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? , 2007, The Prostate.

[19]  S. Barik,et al.  Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells , 2008, Journal of Molecular Medicine.

[20]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[21]  R. Stephens,et al.  Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. , 2008, Cancer research.

[22]  A. Malhotra,et al.  A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). , 2009, Genes & development.

[23]  H. Ito,et al.  Androgen receptor involvement in the progression of prostate cancer. , 2003, Endocrine-related cancer.

[24]  A. Malhotra,et al.  Targeted comparative RNA interference analysis reveals differential requirement of genes essential for cell proliferation. , 2006, Molecular biology of the cell.

[25]  C. Kao,et al.  Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate‐specific antigen‐producing tumors in athymic and SCID/bg mice using LNCaP and lineage‐derived metastatic sublines , 1998, International journal of cancer.

[26]  Y. Wang,et al.  Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival , 2008, Oncogene.

[27]  I. Tannock,et al.  Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. , 2005, Cancer research.

[28]  Charles E. Vejnar,et al.  Integration of microRNA miR-122 in hepatic circadian gene expression. , 2009, Genes & development.

[29]  Leemor Joshua-Tor,et al.  Slicer and the argonautes. , 2007, Nature chemical biology.

[30]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[32]  A. Eklund,et al.  MicroRNA profile analysis of human prostate cancers , 2009, Cancer Gene Therapy.

[33]  Ying Li,et al.  An intron with a constitutive transport element is retained in a Tap messenger RNA , 2006, Nature.

[34]  Christopher P Evans,et al.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells , 2007, Proceedings of the National Academy of Sciences.

[35]  Z. Hall Cancer , 1906, The Hospital.

[36]  Giovanni Vanni Frajese,et al.  The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice , 2008, PloS one.

[37]  J. Richter,et al.  Human let-7a miRNA blocks protein production on actively translating polyribosomes , 2006, Nature Structural &Molecular Biology.

[38]  Donald C. Chang,et al.  Loss of mir-146a function in hormone-refractory prostate cancer. , 2008, RNA.

[39]  N. Zaffaroni,et al.  Towards the definition of prostate cancer-related microRNAs: where are we now? , 2009, Trends in molecular medicine.

[40]  Weidong Wang,et al.  BAF60a Mediates Critical Interactions between Nuclear Receptors and the BRG1 Chromatin-Remodeling Complex for Transactivation , 2003, Molecular and Cellular Biology.

[41]  Kiyoshi Yanagisawa,et al.  Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11‐21 in human lung cancer , 2008, Genes, chromosomes & cancer.

[42]  W. Shou,et al.  FKBP51 and Cyp40 are Positive Regulators of Androgen-dependent Prostate Cancer Cell Growth and the Targets of FK506 and Cyclosporin A , 2009, Oncogene.

[43]  I. Shih,et al.  The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. , 2008, Cancer research.

[44]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[45]  Martin M Matzuk,et al.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. , 2010, Molecular endocrinology.

[46]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[47]  W. Filipowicz,et al.  Inhibition of Translational Initiation by Let-7 MicroRNA in Human Cells , 2005, Science.